By Carlo Martuscelli
AstraZeneca PLC (AZN.LN) said Monday that a phase 3 clinical trial of drug Imfinzi showed the drug was able to improve survival rates in patients with small-cell lung cancer.
The British pharmaceutical company said that Imfinzi combined with chemotherapy showed a clinically meaningful improvement in overall survival for patients with untreated extensive-stage small-cell lung cancer when compared with standard chemotherapy.
AstraZeneca said that the treatment reduced the risk of death by 27%, with a median overall survival of 13 months versus 10.3 months for the standard of care.
In the study, titled Caspian, 33.9% of patients treated with Imfinzi reached the 18-month survival mark, compared with 24.7% for chemotherapy alone.
Small-cell lung cancer is an aggressive and fast-spreading cancer.
Write to Carlo Martuscelli at firstname.lastname@example.org